| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701722 | Journal of Thoracic Oncology | 2017 | 18 Pages |
Abstract
Trimodality therapy including adjuvant hemithoracic IMPRINT, chemotherapy, and P/D is associated with promising OS rates and decreased toxicity in patients with MPM. Dose constraints should be applied vigilantly to minimize serious adverse events.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Fauzia MD, Marjorie G. MD, Donata BS, Abraham J. MD, Ellen D. PhD, Amanda MS, Weiji MS, Zhigang PhD, Prasad S. MD, Kenneth E. MD, Lee M. MD, Valerie W. MD, Andreas MD,